Humana

Humana and Mark Cuban Explore Direct-to-Employer Pharmacy Partnership

Humana's Valuation Revisited Amidst Volatility and Medicare Advantage Uncertainty

Humana shares surge 6.72% after-hours as Barclays raises price target to $315 and institutional investors boost holdings.

哈门那

Humana's 15min Chart Shows RSI Overbought and KDJ Death Cross

ReWalk Robotics

Humana authorizes ReWalk 7 exoskeleton, boosting Lifeward revenue and growth.

Catalyst<ul> <li>A recent Bullish Engulfing candlestick pattern on November 25 signals strong bullish momentum for HUM.</li></ul>Risk<ul> <li>Fund flow analysis indicates a negative overall trend with net outflows from Small, Medium, and Extra-large orders.</li> <li>Analyst ratings for HUM are currently split, with all recent predictions leaning Neutral, indicating a lack of consensus or strong institutional optimism.</li></ul>

Key Factors

Humana (HUM) surges 6.72% in after-hours trading following Barclays raising its price target to $315 and institutional investors increasing holdings.Humana authorizes coverage for the ReWalk 7 exoskeleton, expanding access to the device for spinal cord injury patients and enhancing Lifeward’s revenue potential.Humana collaborates with Mark Cuban on a potential pharmacy partnership aimed at streamlining the drug supply chain and offering transparent pricing through direct-to-employer programs.

Recent Updates

HUM News